35 million women have a sexually transmitted infection (STI) on any given day (2018 data).*1 

Chlamydia trachomatis (CT), Neisseria gonorrhoeae (GC), and Trichomonas vaginalis (TV) are the most prevalent non-viral causes of sexually transmitted infections and accounted for ~$1.1 billion in direct medical costs in 2018.1,2

Cost to the U.S. healthcare system - 2018


But most people with CT, GC, and TV don’t develop symptoms, so infection often goes unrecognized. Left untreated, they can lead to serious adverse outcomes.3-5

Screening and early detection is the best way to diagnose CT, GC, and TV and avoid the downstream consequences of untreated STIs.6

The BD CTGCTV2 FDA-approved assay is designed to detect CT, GC, and TV—the 3 most prevalent non-viral sexually transmitted infections—in a single test.1,6,7

Learn more

*2018 data.
CT, Chlamydia trachomatis; FDA, Food and Drug Administration; GC, Neisseria gonorrhoeae; STI, sexually transmitted infection; TV, Trichomonas vaginalis.

1. Sexually Transmitted Infections Prevalence, Incidence, and Cost Estimates in the United States, CDC. 2021. Accessed 29 Apr 2022. 
2. Kreisel KM et al. Sex Transm Dis. 2021;48(4):208–14.
3. Chlamydia – CDC Fact Sheet, CDC. 2022. Accessed 10 Apr 2022. 
4. Gonorrhea – CDC Fact Sheet, CDC. 2022. Accessed 10 Apr 2022. 
5. Trichomoniasis – CDC Fact Sheet, CDC. 2022. Accessed 10 Apr 2022. 
6. Van Der Pol B et al. Sex Transm Dis. 2021;48(2):134–40.
7. BD CTGCTV2 for BD MAX™ System Package Insert [P0237].